Blog: MS news

Got cog fog?

22 September 2017

Source MS Trust:

Cognition and cognitive symptoms

About half of all people with multiple sclerosis have some degree of problem at some time with aspects of thinking - memory, attention span, planning, decision making, understanding or concentration

Disarm Therapeutics to Begin Developing Therapy that Prevents Axonal Degeneration

22 September 2017

Source Multiple Sclerosis News Today:

Disarm Therapeutics has completed the first round of financing to develop a compound that prevents axonal degeneration in patients with multiple sclerosis (MS) and other neurodegenerative conditions.

New study to look at impact of early treatment with aggressive DMTs

22 September 2017

Source MS Society:

A new study will investigate whether early treatment with aggressive disease modifying therapies (DMTs) could benefit people with MS.

Gut Microbes May Influence Multiple Sclerosis Progression

12 September 2017

Source University of California San Francisco:

Researchers at UC San Francisco have identified specific gut microbes associated with multiple sclerosis (MS) in human patients, and show that these microbes take part in regulating immune responses in mouse models of the disease.

European Commission reverses decision on drug, following QMUL research

12 September 2017

Source Queen Mary University of London:

A drug for multiple sclerosis (MS) has been granted a license by the European Commission, following evidence from Queen Mary University of London (QMUL) that it improves patients’ quality of life and is safer than previously thought.

My Thoughts on Being a Grandparent with a Disability

12 September 2017

Source Multiple Sclerosis News Today:

I had always envisioned that I would be an active and healthy grandparent when the time came — not one with a disability. I was diagnosed with primary progressive multiple sclerosis (PPMS) in the summer of 2010, which also happened to be the same year my first grandchild was born.

Drugs in development

5 September 2017

Source MS Trust:

The development of new drugs is a long and difficult process. Fewer than one or two compounds in 10,000 tested actually make it through to being licensed treatments with many being rejected on safety, efficacy or quality grounds.

Cladribine: NICE looking at new treatment for MS

5 September 2017

Source MS Society:

The European Medicines Agency (EMA) has licensed cladribine (also known as Mavenclad) to treat people with highly active relapsing MS.

The National Institute for Health and Care Excellence (NICE) will now decide whether to make it available on the NHS in England and Wales. The Scottish Medicines Consortium (SMC) will decide for Scotland.

How does it work? Cladribine is currently used as an anti-cancer drug. In MS, the body’s own immune cells...

MS Active Together

5 September 2017

Source MS Society:

If you can't attend the Berkshire MS Therapy Centre for one of our exercise classes then the MS Society MS Active Together videos could be for you.

MS Active together is about helping you be more physically active. Everyone's MS is different, but exercise can help everyone – no matter how MS affects you.

Pages

Category

Archive